Clinical Use of CA 125 and Its Combination Assay with Other Tumor Marker in Patients with Ovarian Carcinoma

Negishi, Y; Furukawa, Toshihito; Oka, Takashi; Sakamoto, Masaru; Hirata, Takao; Okabe, Kazuhiro; Matayoshi, K.; Akiya, K; Soma, Hiroaki

doi:10.1159/000298862

Cited by 21 publications

(7 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies had reported serum levels of CAl25, NB70K, PLAP, HMFG2, CA19-9, CEA and D -D i m e r i n o v a r i a n c a n c e r p a t i e n t s (18,5,16,4,19,17,9), and our results generalIy agree with these reports, with 2 exceptions -HMFG2 and CEA. This is probably explained by the much lower specificity of the original HMFG2 assay data (4) (false positive rate 8% versus 1.9Voo) with the consequence of higher sensitivity, and by the failure of previous studies of CEA to establish a normal range concomitant with patient testing.…”

Section: Discussionsupporting

confidence: 93%

Expression of Multiple Tumour Markers in Serum from Patients with Ovarian Carcinoma and Healthy Women

Ward

McGuckin

Hurst

et al. 1989

Aust NZ J Obst Gynaeco

View full text Add to dashboard Cite

Serum samples from 70 patients with bulky ovarian carcinomas, 46 patients with surgically extirpated Stage I ovarian carcinomas, and 108 aged-matched healthy control subjects were assayed for 10 tumour-associated antigens. Levels of expression of each antigen were progressively increased in treated Stage I and bulky disease patients over healthy controls. Levels of expression in treated Stage I patients inversely reflected the interval between surgery and collection of the sample. For patients with bulky disease, determination of correlation coefficients of expression of each antigen against each other antigen showed that in 9 of 45 such relationships, the coefficients were greater than 0.30, suggesting significant coexpression. The best correlation was found for CA125 and MSA, HMFG2 and MSA, DCA and MSA, and DCA and HMFG2. By multivariate discriminant function analysis, the combination of 2 assays (CA125 and NB/70K) was found to increase specificity of detection of ovarian carcinoma over one assay alone (CA125). Use of more than these 2 assays increased sensitivity only marginally. The attained specificity is insufficient for use as a screening assay for ovarian cancer alone, given the low prevalence in the community of this disease.

show abstract

Section: Discussionsupporting

confidence: 93%

Expression of Multiple Tumour Markers in Serum from Patients with Ovarian Carcinoma and Healthy Women

Ward

McGuckin

Hurst

et al. 1989

Aust NZ J Obst Gynaeco

View full text Add to dashboard Cite

show abstract

“…A combination assay can be used to distinguish be tween malignant and benign diseases, serologically [9], Many investigators [9,10] tried to rule out false-negative cases and to distinguish between a malignant and a benign disease, at an early stage. The high value of tumor markers make it difficult to accurately diagnose a benign tumor.…”

Section: Resultsmentioning

confidence: 99%

Abnormally High Values of CA 125 and CA 19-9 in Women with Benign Tumors

Nagata

Takahashi

Yamane

et al. 1989

Gynecol Obstet Invest

View full text Add to dashboard Cite

Tumor markers have proved to be generally useful for diagnosing and monitoring malignancy. In contrast, high levels of tumor markers disturb us for differing benign disease from malignancy. We had 5 cases with benign disease who showed high values of tumor markers (CA 125 and CA 19–9). In this report, we illustrated 3 patients with endometriosis who showed high values of CA 125 and 2 patients with dermoid cyst who showed high values of CA 19–9. It was impossible to rule out malignant disease in all cases preoperatively. In diagnosing ovarian tumors, bimanual examination, ultrasound, CT scan and tumor markers should all be considered.

show abstract

“…Quantitative serum protein proteomics was used to show that a panel of high abundance acute phase-related proteins could give a better statistical measure of inflammation than the classical marker serum amyloid A (41). Cancer tissue samples could be analyzed to distinguish tumor type and prognosis (146), and a panel of six cancer markers in plasma was found to be useful (147,148). More recently, mass spectrometry-based proteomic approaches have been used as well to discover patterns of diseaserelated protein features related to a specific cancer (65).…”

Section: Plasma Diagnosticsmentioning

confidence: 99%

The Human Plasma Proteome

Anderson¹,

Anderson²

2002

Molecular & Cellular Proteomics

3,887

1,585

View full text Add to dashboard Cite

The human plasma proteome holds the promise of a revolution in disease diagnosis and therapeutic monitoring provided that major challenges in proteomics and related disciplines can be addressed. Plasma is not only the primary clinical specimen but also represents the largest and deepest version of the human proteome present in any sample: in addition to the classical "plasma proteins," it contains all tissue proteins (as leakage markers) plus very numerous distinct immunoglobulin sequences, and it has an extraordinary dynamic range in that more than 10 orders of magnitude in concentration separate albumin and the rarest proteins now measured clinically. Although the restricted dynamic range of conventional proteomic technology (two-dimensional gels and mass spectrometry) has limited its contribution to the list of 289 proteins (tabulated here) that have been reported in plasma to date, very recent advances in multidimensional survey techniques promise at least double this number in the near future. Abundant scientific evidence, from proteomics and other disciplines, suggests that among these are proteins whose abundances and structures change in ways indicative of many, if not most, human diseases. Nevertheless, only a handful of proteins are currently used in routine clinical diagnosis, and the rate of introduction of new protein tests approved by the United States Food and Drug Administration (FDA) has paradoxically declined over the last decade to less than one new protein diagnostic marker per year. We speculate on the reasons behind this large discrepancy between the expectations arising from proteomics and the realities of clinical diagnostics and suggest approaches by which protein-disease associations may be more effectively translated into diagnostic tools in the future.

show abstract

Clinical Use of CA 125 and Its Combination Assay with Other Tumor Marker in Patients with Ovarian Carcinoma

Cited by 21 publications

References 9 publications

Expression of Multiple Tumour Markers in Serum from Patients with Ovarian Carcinoma and Healthy Women

Expression of Multiple Tumour Markers in Serum from Patients with Ovarian Carcinoma and Healthy Women

Abnormally High Values of CA 125 and CA 19-9 in Women with Benign Tumors

The Human Plasma Proteome

Contact Info

Product

Resources

About